Renoprotective Effects of Luteolin: Therapeutic Potential for COVID-19-Associated Acute Kidney Injuries

Acute kidney injury (AKI) has been increasingly reported in critically-ill COVID-19 patients. Moreover, there was significant positive correlation between COVID-19 deaths and renal disorders in hospitalized COVID-19 patients with underlying comorbidities who required renal replacement therapy. It has suggested that death in COVID-19 patients with AKI is 3-fold higher than in COVID-19 patients without AKI. The pathophysiology of COVID-19-associated AKI could be attributed to unspecific mechanisms, as well as COVID-19-specific mechanisms such as direct cellular injury, an imbalanced renin-angiotensin-aldosterone system, pro-inflammatory cytokines elicited by the viral infection and thrombotic events. To date, there is no specific treatment for COVID-19 and its associated AKI. Luteolin is a natural compound with multiple pharmacological activities, including anticoronavirus, as well as renoprotective activities against kidney injury induced by sepsis, renal ischemia and diverse nephrotoxic agents. Therefore, in this review, we mechanistically discuss the anti-SARS-CoV-2 and renoprotective activities of luteolin, which highlight its therapeutic potential in COVID-19-AKI patients.


Introduction
Coronaviruses (CoVs) are positive single-stranded (+ss) RNA viruses that have long been described as causative agents of diseases in mammals and birds [1,2]. Since 2002, three human coronaviruses (HCoVs) were associated with severe respiratory disease outbreaks that resulted in a large number of cases and deaths in several countries [3,4]. These three HCoVs include Severe Acute Respiratory Syndrome-CoV (SARS-CoV), which was discovered in China in 2002-2003 [5], followed by Middle East Respiratory Syndrome-CoV (MERS-CoV), first identified in Saudi Arabia in 2012 [6], and lastly the novel SARS-CoV-2 that caused the Coronavirus Disease 2019 (COVID- 19) pandemic. SARS-CoV-2 was first reported in Wuhan, China in December 2019, and has resulted in millions of deaths worldwide [4,7,8].

Materials and Methods
The present article was carried out based on a survey of literature of luteolin and AKI. The search, performed in the PubMed database, included studies published until September 2022, and used the following keywords: Luteolin and COVID-19; Luteolin and SARS-CoV-2; Luteolin and acute kidney injury; Luteolin and acute kidney failure; Luteolin and SARS-CoV-2-induced acute kidney injury; Luteolin and SARS-CoV-2-induced acute renal injury; and Luteolin and COVID-19-induced acute kidney injury. Reported data of renoprotective effects of luteolin assessed by in-vitro assays or experimental models of chronic renal injury were not selected. Only studies in which the renoprotective effects of luteolin were investigated using in-vivo experimental models of AKI were selected. Results obtained from crude extract or beverages, as well as a combination of luteolin with other bioactive drugs, were not considered. Only scientific publications published in the English language were selected.

Materials and Methods
The present article was carried out based on a survey of literature of luteolin and AKI. The search, performed in the PubMed database, included studies published until September 2022, and used the following keywords: Luteolin and COVID-19; Luteolin and SARS-CoV-2; Luteolin and acute kidney injury; Luteolin and acute kidney failure; Luteolin and SARS-CoV-2-induced acute kidney injury; Luteolin and SARS-CoV-2-induced acute renal injury; and Luteolin and COVID-19-induced acute kidney injury. Reported data of renoprotective effects of luteolin assessed by in-vitro assays or experimental models of chronic renal injury were not selected. Only studies in which the renoprotective effects of luteolin were investigated using in-vivo experimental models of AKI were selected. Results obtained from crude extract or beverages, as well as a combination of luteolin with other bioactive drugs, were not considered. Only scientific publications published in the English language were selected.

Anti-SARS-CoV-2 Activities of Luteolin
Polyphenolic plant-derived compounds, including luteolin, have shown anti-viral activities against multiple viruses, including coronaviruses [45][46][47][50][51][52]. Since the emergence of SARS-CoV-1, several research groups have tested polyphenols, such as some flavonoids and other natural compounds for SARS-CoV-1 anti-viral activities [53]. In one study, small molecules derived from Chinese herbs were tested for binding to SARS-CoV-1 S2 domain of S protein using affinity chromatography [54]. Luteolin was identified as a compound that bound to S2 domain and inhibited the entry of both HIV-luc/SARS pseudotyped virus and SARS-CoV-1 live virus into Vero E6 cells with IC50s of 9.02 and 10 µM, respectively. Similarly, the threat of the COVID-19 pandemic has urged researchers to discover and develop effective anti-viral drugs against SARS-CoV-2. Given the efficacy of luteolin in inhibiting SARS-CoV-1 viral entry, it was tested by several research groups for anti-SARS-CoV-2 activities. Several molecular docking studies have shown that luteolin bound with high affinity to SARS-CoV-2 Mpro, PLpro, RdRP and ACE2 receptor [55][56][57][58][59][60][61][62][63][64][65][66][67]. Molecular docking studies were confirmed by fluorescence resonance energy transfer assay (FRET), which demonstrated that luteolin inhibited Mpro activity with IC50s of 11.81 µM and 20.2 µM [68,69]. Using an in-vitro enzymatic assay, luteolin was also shown to inhibit RdRp with an IC50 of 4.6 ± 0.3 µM [70]. Furthermore, co-treatment or pre-treatment of SARS-CoV-2 virus with Vitis vinifera leaf extract, containing derivatives of luteolin and other flavonoids, were the most effective in the inhibition of SARS-CoV-2 infection of Vero cells (80% at 10 µM) [71]. It was shown that luteolin and other extract components bound to S protein and blocked the attachment of SARS-CoV-2 to ACE2. All the previous studies demonstrate that luteolin is a promising anti-viral against SARS-CoV-2, which targets multiple viral proteins in the viral life cycle ( Figure 2). extract components bound to S protein and blocked the attachment of SARS-CoV-2 to ACE2. All the previous studies demonstrate that luteolin is a promising anti-viral against SARS-CoV-2, which targets multiple viral proteins in the viral life cycle ( Figure 2).

Figure 2.
Luteolin is a potential anti-viral against SARS-CoV-2, and could be an effective therapeutic for COVID-19. Luteolin binds to S protein, and inhibits the binding of SARS-CoV-2 to ACE2. Luteolin binds with high affinity to SARS-CoV-2 main protease (Mpro), papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp) and ACE2 as shown by molecular docking studies. The inhibitory activity of luteolin for Mpro and RdRp has been confirmed by enzymatic assays. This figure was adapted from "Life Cycle of Coronavirus", by BioRender.com (2022), with modifications. Retrieved from https://app.biorender.com/biorender-templates (accessed on 27 January 2022)

AKI: Criteria, Mechanisms and Experimental Models
AKI is defined as an abrupt and reversible decline in renal functions, which might progress to chronic kidney disease (CKD) [72]. AKI is diagnosed by criteria that include an increase in serum creatinine (SCr) ≥0.3 mg/dL (≥26.5 µ mol/L) within 48 h; however, an absolute rise in SCr ≥ 2-3 times the baseline has been used as a criterion for the diagnosis and classification of advanced stages of AKI. A decrease of urinary output to less than 0.5 mL kg −1 h −1 for 6h is also used as a criterion for diagnosis of AKI [73,74]. In general, the mechanisms underlying AKI genesis are oxidative stress, inflammation and apoptosis. The oxidative stress is evidenced by a decrease in anti-oxidant enzyme activities, an increase in lipid peroxidation and elevated levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS). The inflammation is characterized by a significant increase in renal expression of proinflammatory cytokines (e.g., TNF-α, IL-1β and IL-6), elevated numbers of inflammatory cells infiltrating the renal tissue and renal interstitial fibrosis. On the other hand, apoptosis is characterized by the increased expression of proapoptotic proteins (e.g., Bax) and decreased expression of antiapoptotic protein (e.g., Bcl-2) [74,[75][76][77][78][79].

Initial Considerations
Even though the present review aims to show only the experimental findings of the renoprotective effect of Lutein on AKI, its effects on CKD have already been reported and might be discussed in a further study. For example, it was observed Luteolin-containing

AKI: Criteria, Mechanisms and Experimental Models
AKI is defined as an abrupt and reversible decline in renal functions, which might progress to chronic kidney disease (CKD) [72]. AKI is diagnosed by criteria that include an increase in serum creatinine (SCr) ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h; however, an absolute rise in SCr ≥ 2-3 times the baseline has been used as a criterion for the diagnosis and classification of advanced stages of AKI. A decrease of urinary output to less than 0.5 mL kg −1 h −1 for 6h is also used as a criterion for diagnosis of AKI [73,74]. In general, the mechanisms underlying AKI genesis are oxidative stress, inflammation and apoptosis. The oxidative stress is evidenced by a decrease in anti-oxidant enzyme activities, an increase in lipid peroxidation and elevated levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS). The inflammation is characterized by a significant increase in renal expression of proinflammatory cytokines (e.g., TNF-α, IL-1β and IL-6), elevated numbers of inflammatory cells infiltrating the renal tissue and renal interstitial fibrosis. On the other hand, apoptosis is characterized by the increased expression of proapoptotic proteins (e.g., Bax) and decreased expression of antiapoptotic protein (e.g., Bcl-2) [74][75][76][77][78][79].

Initial Considerations
Even though the present review aims to show only the experimental findings of the renoprotective effect of Lutein on AKI, its effects on CKD have already been reported and might be discussed in a further study. For example, it was observed Luteolin-containing herbal products reduced the progressive renal fibrosis induced by Unilateral ureteral obstruction (UUO), a model used for elucidating the pathogenesis of obstructive nephropathy and mechanisms responsible for progressive renal fibrosis, characterized by glomerular sclerosis and/or progressive interstitial fibrosis [85][86][87][88][89].
Several studies have reported that luteolin protects against I/R-induced renal injury. Hong et al. [37] reported that the oral administration of luteolin (40 mg/kg) attenuated renal histological lesions and reduced BUN and SCr levels in I/R Sprague-Dawley rats. In addition, luteolin treatment induced renal superoxide dismutase (SOD) and catalase (CAT) activities with a simultaneous reduction of renal malondialdehyde (MDA) and myeloperoxidase (MPO) levels. Moreover, serum levels of TNF-α, IL-1β and IL-6 were reduced in luteolin-treated I/R rats, which was accompanied by reduced activity of renal nuclear factor kappa B (NF-κB) [37]. In line with the previous study, Liu et al. [98] demonstrated that pre-treatment with luteolin significantly reduced the levels of TNF-α, IL-1β and IL-6, restored cellular viability of damaged renal tissue and reduced the population of apoptotic cells in I/R mice. This was accompanied with increased Bcl-2 and reduced Bax expression and reduced caspase-3 activation [98]. Furthermore, Kalbolandi et al. [99] reported that oral pre-treatment with 50 mg/kg luteolin for 3 days lowered SCr and BUN levels, attenuated renal pathological changes and increased the enzymatic activities of S OD, glutathione peroxidase (GPx) and CAT in kidneys of I/R rats. Moreover, there was a significant reduction in levels of renal tissue MDA, Nrf2 and miR320 in luteolin-pre-treated compared to untreated I/R rats [99].

Renoprotective Effects of Luteolin against Sepsis-Induced AKI
Sepsis is defined as a life-threatening multiorgan dysfunction caused by a dysregulated host response to infection, and is the main cause of AKI in critically-ill patients. Sepsisinduced AKI is characterized by severe inflammatory complications, high morbidity and mortality [77,100,101]. Experimental models of sepsis-induced AKI include: (1) injection of bacteria or endogenous toxins (e.g., LPS) into the peritoneum or blood; and (2) release of intestinal excreta by cecal ligation and puncture (CLP) or colon ascendens stent peritonitis (CASP) [90,102]. LPS-AKI is an acute model that is usually induced in rodents with 10-15 mg/kg LPS and terminates at 72-96 h. LPS interacts with Toll-like receptor 4 (TLR-4) on host immune cells, which induces the production of proinflammatory cytokines such as IL-1, TNF-α and IL-6, leading to inflammation [79,[103][104][105]. In 2016, Xin et al. [106] showed that pre-treatment with 40 mg/kg luteolin for 3 days attenuated the LPS-induced renal damage, tubular necrosis and oxidative stress in mice. Attenuation of renal damage in luteolin pre-treated mice was supported by reduced levels of BUN and Scr and renal TNF-α, IL-1β, MCP-1, ICAM-1, NF-κB, caspase-3 [106]. The CLP model is the most frequently used model of sepsis-induced AKI, due to its simplicity, good results and reproduction of typical symptoms of bacterial peritonitis observed in humans [107,108]. Briefly, cecum is ligated from the distal to the ileocecal valve, followed by needle punctures to extrude stool into the abdominal cavity [102,107]. In a recent study by Wang et al. [42], it was observed that gastric gavage administration of 20 mg/kg/day luteoloside, 2h before the operation and for 5 days after the operation, attenuated kidney damage in CLP-induced septic mice. It was shown that luteoloside significantly reduced the production of proinflammatory cytokines, which was accompanied by inhibition of the secretion and translocation of mobility group box (HMGB)1 and HMGB1-mediated activation of TLR4/NF-κB/MAPKs signaling pathways [42].

Renoprotective Effects of Luteolin against Nephrotoxic Substances-Induced AKI
It has been reported that some compounds are potentially nephrotoxic, depending on the dose, route and duration of exposure [109,110]. For example, therapeutic drugs of different pharmacological classes (e.g., anti-cancer and antibiotics agents), heavy metals (e.g., Pb and Hg 2+ ), exogenous toxins (e.g., insecticides, snake and spider poisons and industrial chemicals) and endogenous vasoactive peptides (e.g., angiotensin II) might cause renal damage with varying severity, which might range from tubular dysfunctions to severe renal failure, occasionally leading to death [111][112][113][114][115][116].

Renoprotective Effects of Luteolin against Glycerol-Induced AKI
Rhabdomyolysis is a syndrome in which the breakdown of skeletal muscle leads to the release of intracellular proteins and toxic compounds into circulation, which results in oxidative damage and the inflammation of different organs, including the kidneys [117,118]. AKI is considered a common complication of rhabdomyolysis, and accounts for the high mortality [119,120]. Glycerol-induced AKI is an experimental model that resembles renal injury due to rhabdomyolysis [121,122]. Oyagbemi et al. [123] reported that pre-treatment of Wistar albino rats with 100 and 200 mg/kg of luteolin for 7 days resulted in a significant reduction of oxidative stress markers, which were induced by administration of glycerol (10 mL/kg BW, 50% v/v in sterile saline, i.m.). Luteolin treatment attenuated the increase of renal protein carbonyl and xanthine oxidase, and increased the activities of renal GPx, glutathione S-transferase and glutathione reductase (GR). Moreover, luteolin downregulated the expression of KIM-1 and activity of NF-κB that were induced by glycerol [123].

Renoprotective Effects of Luteolin against Pharmacological Agents-Induced AKI
Cisplatin, Doxorubicin and Methotrexate are effective chemotherapy agents that are frequently used in the treatment of cancer and autoimmune diseases with significant renal toxicity, which limits their uses [112,124]. In rodents, the intraperitoneal (i.p.) administration of high doses of cisplatin (6-40 mg/kg), doxorubicin (2 mg/kg) or methotrexate (20 mg/kg) can induce, within 72 h, renal inflammation, oxidative stress and calcium overload, leading to significant proximal tubular toxicity, with tubular cell necrosis and apoptosis. This is usually followed by increased vascular resistance and decreased GFR, comparable with those of humans [125,126]. Domitrović et al. [35] showed that i.p. injection of luteolin (10 mg/kg), once daily for 3 days following a single cisplatin i.p. injection (10 or 20 mg/kg) in mice, significantly reduced renal dysfunction, inflammation and apoptosis induced by cisplatin. The improvement in renal function was supported by lower SCr, BUN levels and attenuated histological damages, which were accompanied by reduced renal NF-κB activity and reduced levels of TNF-α, COX-2, p53 and caspase-3 in luteolin-treated compared to untreated mice [35]. These results were in agreement with a previous study by Kang et al. [127] that showed reduced BUN, SCr, p53, PUMA-α, Bax and caspase-3 following luteolin treatment (50 mg/kg for 3 days) in cisplatin-treated C57BL/6 mice (20 mg/kg) [127]. Luteolin has also been shown to significantly improve renal function and reduce tubular cell damage, oxidative stress and apoptosis induced by doxorubicin and methotrexate. Luteolin treatment (50 and 100 mg/kg) attenuated renal dysfunction and oxidative stress induced by doxorubicin (2 mg/kg) and methotrexate (20 mg/kg) treatments. The renoprotective effect of luteolin was evidenced by lower renal MDA, ROS and RNS levels, accompanied by higher glutathione (GSH) and anti-oxidant enzyme (SOD, CAT and GPx) activities in luteolin-treated animals compared to the control group. Moreover, luteolin treatment reduced proinflammatory molecules (NF-κB, TNF-α and IL-1β) and proapoptotic proteins (Bax, caspases-3 and -9), and increased antiapoptotic (Bcl-2) proteins compared to untreated animals [43,44].
Colistin, a polymyxin antibiotic medication used as the last resort treatment for multidrug-resistant gram-negative infections, has relevant therapeutic use in clinical practice, limited by its nephrotoxicity [128,129]. In 2016, Arslan et al. [36] reported that i.p. administration of luteolin (10 mg/kg) for seven days was capable of preventing colistin-induced nephrotoxicity, as demonstrated by lowered SCr levels, and the number of apoptotic cells and renal damages compared to animals that only received colistin (480,000 IU/kg/day) [36].

Renoprotective Effects of Luteolin against Heavy Metals-Induced AKI
Human exposure to heavy metals; such as cobalt (Co 3+ ), mercury (Hg 2+ ), lead (Pb 2+ ), chromium (Cr 4+ ) and iron (Fe 2+ ), is strongly associated with renal diseases [130][131][132]. Nitrilotriacetate (Fe-NTA) is a strong oxidant and potent nephrotoxic agent which generates highly reactive hydroxyl radical causing injuries of various organs, including kidneys. Fe-NTA-induced damage includes proximal tubular cell injury and necrosis with oxidative stress and progressive interstitial renal fibrosis [133,134]. In a study by Sultana et al. [135], the pre-treatment of Wistar rats with luteolin (10 and 20 mmol/kg) for 7 consecutive days resulted in the significant attenuation of renal lipid peroxidation and renal dysfunction induced by i.p. injection of Fe-NTA (9 mg Fe/kg). The protection of kidneys against Fe-NTA-induced damage was further demonstrated by reduced SCr and BUN, hydrogen peroxide levels, ornithine decarboxylase activity and [3H] thymidine incorporation into renal DNA [135]. Tan et al. [38] also showed that oral gavage administration of luteolin (80 mg/kg) significantly reduced HgCl 2 -induced renal damage, as shown by alleviated inflammation and oxidative stress evidenced by decreased MDA levels and NF-κB activation, as well as elevation of GSH levels. Moreover, it was observed that luteolin treatment promoted nuclear translocation of Nrf2, which was associated with increased renal expression of anti-oxidant enzymes, hemeoxygenase-1 (HO-1) and quinone-acceptor 1 (NQO1) [38]. In 2020, Oyagbemi et al. [40] reported that treatment of rats with luteolin (100 and 200 mg/kg) reversed cobalt-induced oxidative stress in kidneys by reducing renal H 2 O 2 , MDA, NO and increasing GSH, GPx and GST activities. In addition, renal tissue lesions were attenuated with reductions in serum MPO activity, renal NF-κB activity and Kim-1 expression in luteolin-treated rats compared to untreated animals [40]. Similarly, luteolin treatment protected against renal injury in Pb-treated male Wistar rats. Oral treatment with luteolin (50 mg/kg) significantly attenuated renal histological damages in Pb-treated Wistar rats (20 mg/kg, i.p), with significant reductions of SCr and BUN levels and renal MDA levels and the induction of anti-oxidant enzyme activities (SOD, CAT, GPx and GR). Additionally, luteolin inhibited the reduction in Nfe212 and Homx1 mRNA expression in Pb-treated rats, and reduced the production of proinflammatory markers (TNF-α, IL-1β and NO) and apoptotic related proteins while upregulating the expression of antiapoptotic proteins [136]. Awoyomi et al. [137] showed that the pre-treatment with Luteolin (100 and 200 mg/kg) reduced acute kidney injuries induced by potassium dichromate (K 2 Cr 2 O 7 ), at dose of 30 mg/kg, through anti-oxidantive and radical scavenging mechanisms. Luteolin reduced oxidative stress indicators, augmented anti-oxidant mechanisms and serum Nitric oxide level, lowered the expressions of injury molecule (Kim-1) and up-regulated the renal, nuclear factor erythroid 2-related factor 2 (Nrf2) [137].
Bisphenol A, a nephrotoxic industrial chemical used primarily in the production of polycarbonate plastics and epoxy resins, is a recognized nephrotoxic agent with widespread daily human exposure [138]. It was shown that orally administered luteolin (100 and 200 mg/kg) protected the kidneys and increased renal Nrf2 and HO-1 expression in bisphenol-treated animals. Moreover, BUN, SCr, serum uric acid levels and proinflammatory mediators (TNF-α, IL-6 and IL-1 β) were reduced in luteolin-treated compared to untreated rats [39], Table 1. Table 1. Renoprotective effects of luteolin in animal models of acute kidney injury (AKI).

Experimental Model Renoprotective Effect Mechanism of Action Reference
Renal ischemia-reperfusion injury Luteolin (40 mg/kg) inhibited the increase of BUN and SCr Reduced lipid peroxidation; Restored the depleted renal anti-oxidant enzymes (SOD, CAT and GPx); Reduced MPO activity and expression of TNF-α, IL-1β and IL-6 via suppression of NF-κB; Reduced the population of apoptotic cells with increased Bcl-2 expression accompanied by reduced Bax expression and caspase-3 activity [37,98] Luteolin (50 mg/kg) inhibited the increase of BUN and SCr Reduced the lipid peroxidation and increased glutathione levels; Restored the depleted renal SOD, CAT and GPx; Increased expression of Nrf2 and miR320 [99] Acute Kidney Injury Induced by Sepsis

Experimental Model
Renoprotective Effect Mechanism Reference

Renoprotective Effects of Luteolin against Angiotensin II-Induced AKI
Several studies have provided evidence of the involvement of the renin-angiotensinaldosterone-system (RAAS) in the pathogenesis and progression of the nephropathies through renal vasoconstriction, inflammation, oxidative stress, microthrombosis and proproliferative effects [139][140][141][142][143]. The imbalance of RAAS is also among the suggested mechanisms of AKI development in COVID-19 patients [144,145]. Recently, Liu et al. [41] investigated the therapeutic effects of oral administration of luteolin (100 mg/kg/day for 4 weeks) on angiotensin II (AngII)-induced renal damage in apolipoprotein E-deficient (Apoe −/− ) mice. It was reported that SCr levels and renal collagen I and III expressions were reduced in animals that were pre-treated with luteolin compared to untreated animals. Expression of IL-1β, IL-6, TNF-α and IL-10 were also suppressed in kidney tissues of the luteolin-pre-treated animals, compared to animals who received only Ang II treatment ( Figure 3). Furthermore, luteolin inhibited the significant increase in LC3 protein expression, and significantly reduced p62 protein expression in kidney tissues of Ang II-treated animals [41].
Biomolecules 2022, 12, x FOR PEER REVIEW 9 of 18 proliferative effects [139][140][141][142][143]. The imbalance of RAAS is also among the suggested mechanisms of AKI development in COVID-19 patients [144,145]. Recently, Liu et al. [41] investigated the therapeutic effects of oral administration of luteolin (100 mg/kg/day for 4 weeks) on angiotensin II (AngII)-induced renal damage in apolipoprotein E-deficient (Apoe −/− ) mice. It was reported that SCr levels and renal collagen I and III expressions were reduced in animals that were pre-treated with luteolin compared to untreated animals. Expression of IL-1β, IL-6, TNF-α and IL-10 were also suppressed in kidney tissues of the luteolin-pre-treated animals, compared to animals who received only Ang II treatment ( Figure 3). Furthermore, luteolin inhibited the significant increase in LC3 protein expression, and significantly reduced p62 protein expression in kidney tissues of Ang II-treated animals [41]. Luteolin is a potential renoprotective drug against COVID-19-associated AKI. Luteolin attenuates oxidative stress and lipid peroxidation by acting as an anti-oxidant and restoring antioxidant enzyme activities, which detoxify reactive oxygen species (ROS). Luteolin also acts as an anti-inflammatory by inhibiting activation of NF-kB, which lowers production of pro-inflammatory Figure 3. Luteolin is a potential renoprotective drug against COVID-19-associated AKI. Luteolin attenuates oxidative stress and lipid peroxidation by acting as an anti-oxidant and restoring antioxidant enzyme activities, which detoxify reactive oxygen species (ROS). Luteolin also acts as an anti-inflammatory by inhibiting activation of NF-kB, which lowers production of pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β). Moreover, luteolin is an antiapoptotic which inhibits p53 induction and Bax expression while increasing Bcl-2 expression. This figure was created with BioRender.com (accessed on 25 January 2022).
Many of the pathologic features and clinical manifestations of renal injury caused by SARS-CoV-2 infection are similar to those described in kidney impairment induced by different etiologies [74,78,79]. Furthermore, glomerular and tubular damages are secondary to ischemia with redistribution of blood flow from renal medulla to the cortex, deterioration of microcirculatory oxygenation, generation of local inflammatory mediators, pro-fibrotic agents and ROS [17][18][19]. Thus, the significant renoprotective effects of luteolin in diverse experimental models of AKI, which are mediated by anti-oxidant, anti-inflammatory and antiapoptotic activities, warrant future investigation of luteolin as a potential therapeutic in COVID-19-associated AKI. Moreover, luteolin has shown renoprotective effects against AngII-induced renal damage. Since the imbalance of RAAS with generation of inflammatory mediators, oxidative stress and microthrombosis have been suggested as specific mechanisms of COVID-19-associated AKI, we believe that luteolin would be effective in managing COVID-19-associated AKI [142,146].
AKI is one of the clinical complications that represents poor prognosis, and is associated with high mortality of SARS-CoV-2-infected patients in ICU settings. The documented anti-viral and renoprotective activities of Luteolin support its further investigation as a potential drug against COVID-19-associated AKI. We believe that multiple pharmacological actions of luteolin would mitigate clinical manifestations of COVID-19, and reduce the disease progression and mortality. Luteolin can also be used as a prototype for the development of synthetic analogs with enhanced anti-inflammatory and anti-viral activities, and a better safety profile to control the current pandemic. However, two important observations must be done. Firstly, COVID-19 is a multifactorial disease, and the management of AKI with luteolin could not be the solution to improve the disease and mortality rate. Secondly, a large number of experimental and clinical studies need to be performed to ensure pharmacology safety and efficiency prior to use in the human population.